Follow us for Davos updates

Merck

To find out more about
Merck
visit:
Merck
For more information visit:
Visit Website

Impacting Life & Health With Science

Drug discovery is the process of identifying and developing new pharmaceutical drugs to treat various diseases. It is a complex, multi-step process that can take many years and involve significant costs. There are huge challenges that can be faced when trying to get a new drug onto the market. Traditionally, the way in which researchers go about discovering new drugs has to screen a huge library of compounds and identify every single molecule that has potential. Then they conduct numerous experiments to be able to optimise that molecule to a drug candidate which means increasing its potency. Even after being successful through labs, a lot of these molecules fail as they go through clinical phases. Furthermore, statistically, only about 10% of the compounds that go through phase one make it to the market. It takes on average about twelve years to bring one drug to market. Millions of people are waiting on the promise of new drugs and therapies to come to market, while at the same time, new diseases continue to emerge. 

AI in drug discovery is the use of artificial intelligence techniques to assist in the process of identifying and developing new drugs. This can include tasks such as analysing large amounts of scientific literature, predicting the potential efficacy of a drug candidate and identifying new targets for drug development. The goal of using AI in drug discovery is to speed up the process and improve the chances of success in finding new treatments for diseases.

Merck  is a global diversified science and technology company that has been advancing human progress since 1668 and draws on almost 360 years of history.  Merck  has leadership positions in three fast-growing markets: life science, healthcare, and electronics. “We are creating discoveries and pushing the boundaries of science of what's possible,” says Ashwini Ghogare, Head of Artificial Intelligence and Automation in Drug Discovery. 

The popularity and widespread use of AI-based methods have increased dramatically over the last decade and have touched almost every facet of life, including life sciences. AI and automation technologies have the potential to revolutionise the discovery of new and more effective drugs ultimately accelerating the delivery of new therapies for patients. AI has the potential to offer over US$70 billion in savings for the drug discovery process, and save up to 70% of time and cost.

As part of this process,  Merck  has developed AIDDISON™ software that combines AI, machine learning, and computer-aided drug design methods, which is a valuable toolkit for its customers in the discovery stages. Now,   Merck’s customers can accelerate it to lead identification and lead manufacturability by deploying AIDDISON™ software to shorten the lead discovery phase, and increasing the success rate in the delivery of new therapies for patients.

As the new megatrend of AI redefines the 21st century,  Merck  looks forward to serving as an enabling solutions provider and trusted supply partner to customers worldwide. The AI megatrend harnesses a diverse mix of experts, processes, and technologies across biotech, software, and engineering, and embracing a multi-disciplinary approach to science will be vital to help solve many of humanity's biggest challenges.

Drug discovery is the process of identifying and developing new pharmaceutical drugs to treat various diseases. It is a complex, multi-step process that can take many years and involve significant costs. There are huge challenges that can be faced when trying to get a new drug onto the market. Traditionally, the way in which researchers go about discovering new drugs has to screen a huge library of compounds and identify every single molecule that has potential. Then they conduct numerous experiments to be able to optimise that molecule to a drug candidate which means increasing its potency. Even after being successful through labs, a lot of these molecules fail as they go through clinical phases. Furthermore, statistically, only about 10% of the compounds that go through phase one make it to the market. It takes on average about twelve years to bring one drug to market. Millions of people are waiting on the promise of new drugs and therapies to come to market, while at the same time, new diseases continue to emerge. 

AI in drug discovery is the use of artificial intelligence techniques to assist in the process of identifying and developing new drugs. This can include tasks such as analysing large amounts of scientific literature, predicting the potential efficacy of a drug candidate and identifying new targets for drug development. The goal of using AI in drug discovery is to speed up the process and improve the chances of success in finding new treatments for diseases.

Merck  is a global diversified science and technology company that has been advancing human progress since 1668 and draws on almost 360 years of history.  Merck  has leadership positions in three fast-growing markets: life science, healthcare, and electronics. “We are creating discoveries and pushing the boundaries of science of what's possible,” says Ashwini Ghogare, Head of Artificial Intelligence and Automation in Drug Discovery. 

The popularity and widespread use of AI-based methods have increased dramatically over the last decade and have touched almost every facet of life, including life sciences. AI and automation technologies have the potential to revolutionise the discovery of new and more effective drugs ultimately accelerating the delivery of new therapies for patients. AI has the potential to offer over US$70 billion in savings for the drug discovery process, and save up to 70% of time and cost.

As part of this process,  Merck  has developed AIDDISON™ software that combines AI, machine learning, and computer-aided drug design methods, which is a valuable toolkit for its customers in the discovery stages. Now,   Merck’s customers can accelerate it to lead identification and lead manufacturability by deploying AIDDISON™ software to shorten the lead discovery phase, and increasing the success rate in the delivery of new therapies for patients.

As the new megatrend of AI redefines the 21st century,  Merck  looks forward to serving as an enabling solutions provider and trusted supply partner to customers worldwide. The AI megatrend harnesses a diverse mix of experts, processes, and technologies across biotech, software, and engineering, and embracing a multi-disciplinary approach to science will be vital to help solve many of humanity's biggest challenges.

View more videos

Impacting Life & Health With Science

Drug discovery is the process of identifying and developing new pharmaceutical drugs to treat various diseases. It is a complex, multi-step process that can take many years and involve significant costs. There are huge challenges that can be faced when trying to get a new drug onto the market. Traditionally, the way in which researchers go about discovering new drugs has to screen a huge library of compounds and identify every single molecule that has potential. Then they conduct numerous experiments to be able to optimise that molecule to a drug candidate which means increasing its potency. Even after being successful through labs, a lot of these molecules fail as they go through clinical phases. Furthermore, statistically, only about 10% of the compounds that go through phase one make it to the market. It takes on average about twelve years to bring one drug to market. Millions of people are waiting on the promise of new drugs and therapies to come to market, while at the same time, new diseases continue to emerge. 

AI in drug discovery is the use of artificial intelligence techniques to assist in the process of identifying and developing new drugs. This can include tasks such as analysing large amounts of scientific literature, predicting the potential efficacy of a drug candidate and identifying new targets for drug development. The goal of using AI in drug discovery is to speed up the process and improve the chances of success in finding new treatments for diseases.

Merck  is a global diversified science and technology company that has been advancing human progress since 1668 and draws on almost 360 years of history.  Merck  has leadership positions in three fast-growing markets: life science, healthcare, and electronics. “We are creating discoveries and pushing the boundaries of science of what's possible,” says Ashwini Ghogare, Head of Artificial Intelligence and Automation in Drug Discovery. 

The popularity and widespread use of AI-based methods have increased dramatically over the last decade and have touched almost every facet of life, including life sciences. AI and automation technologies have the potential to revolutionise the discovery of new and more effective drugs ultimately accelerating the delivery of new therapies for patients. AI has the potential to offer over US$70 billion in savings for the drug discovery process, and save up to 70% of time and cost.

As part of this process,  Merck  has developed AIDDISON™ software that combines AI, machine learning, and computer-aided drug design methods, which is a valuable toolkit for its customers in the discovery stages. Now,   Merck’s customers can accelerate it to lead identification and lead manufacturability by deploying AIDDISON™ software to shorten the lead discovery phase, and increasing the success rate in the delivery of new therapies for patients.

As the new megatrend of AI redefines the 21st century,  Merck  looks forward to serving as an enabling solutions provider and trusted supply partner to customers worldwide. The AI megatrend harnesses a diverse mix of experts, processes, and technologies across biotech, software, and engineering, and embracing a multi-disciplinary approach to science will be vital to help solve many of humanity's biggest challenges.

MLP

MLP: Financial competence and experience of over 50 years
View Video

Hoegh

Delivering energy independence
View Video

PARETO SECURITIES

Pareto Securities Financing the Energy Transition
View Video

Switch Health

A 21st century approach to health care.
View Video

Magnit

Reimagine Your Talent Supply Chain & Contingent Workforce with Magnit Platform
View Video

GAIA-X

Gaia-X: Creating Trusted Data Infrastructure
View Video

Fritz Winter

Supplier for automotive industries.
View Video

Fasanara Capital

Fasanara Capital: Fintech Lending Pioneer
View Video

Kroll

Cyber in 2023: Geopolitical & Economic Risks
View Video

Phenogy

We energize the future. Sustainably
View Video

TDK Ventures

TDK Ventures for Impact-Scaling Entrepreneurs
View Video

Trivium Packaging

Shaping the Future of Packaging
View Video

Globacap

The Next Evolutionary Stage of Private Capital Markets
View Video

Hydrogen Pro

Enabling the future with green hydrogen
View Video

Voyager Space

Building our future in space & on earth
View Video

Corbion

Global leader in sustainable solutions
View Video

Jumptuit

Jumptuit: A Real-Time Data Revolution
View Video

Air Liquide

Air Liquide: Inventing the Future
View Video

Trellix

Adapting at the Speed of Cyber Threats
View Video

Airwallex

Enabling businesses to grow beyond borders
View Video

CGAP - World Bank

CGAP: Helping build Financial Systems For All
View Video

Matrix Holograms

The tutors that are using AI to teach.
View Video

NCC Group

Shaping the Future of Cyber Security
View Video

Clicdata

The data revolution of the 21st century.
View Video

Birdeye

The Convenience of Digital Customer Experience
View Video

Brex

The opportunity of globally distributed spend
View Video

Secureworks

Scaling Cybersecurity with Data-Driven Trust
View Video

Lukka

Superior, secure & scalable data solutions
View Video

Saxbys

Real-World Education for Tomorrow's Leaders
View Video

Novastone

Entrepreneurship through Acquisition
View Video

U-Earth

A new breathing standard for the planet.
View Video

Ecowatt

Ecowatt: A green investment platform
View Video

Nishimura & Asahi

View Video

Merck

Impacting Life & Health With Science
View Video

Proterra

Meet the company driving the all-electric era
View Video

Flow Traders

View Video

InterContinental Energy

Green Hydrogen Powering the Future
View Video

Michigan Economic Development Corporation

The Future Rides on Michigan
View Video

Pinochle

Securing the AI Economy: Good and Bad Bots
View Video

JGC Holding Corporation

JGC Holdings: Enhancing Planetary Health
View Video

Crisp

Using collaborative tech to solve food waste
View Video

H&M Foundation

Enabling an Inclusive and Sustainable World
View Video

CyberVerse Advisors

CyberVerse Advisors - The Leading Cyber Advisory Companying Bringing Systems Together
View Video

Harvard Management Company

Harvard Management Company - Getting to Net Zero
View Video

Schoeller Allibert

Schoeller - Using a cradle-to-cradle approach to make returnable packaging more sustainable
View Video

Geopolymer

Geopolymer Solutions - Utilising a Time Tested Process for the Future Health of the Planet
View Video

Li-Cycle

Li-Cycle - Recovering the Value and Materials Within
View Video

Straumann

Straumann Group - Digitalization, entrepreneurship and sustainability to unlock the potential of people’s lives.
View Video

Provivi

Provivi - Developing Pheromone Solutions for Crop Protection
View Video

Boson Energy

Boson Energy - Enabling the Energy Transition with Waste
View Video

AXA Investment Managers

AXA Investment Managers - Working to Value Creation in Real Assets
View Video

Cambridge Associates

Cambridge Associates - Investing for Global Change
View Video

Svante

Svante - The ‘’Picks and Shovels’’ of the Carbon Marketplace
View Video

Eventide

Eventide Asset Management - Leveraging the Power of Capital
View Video

Toom

Toom Baumarkt - the sustainable, one-stop hardware solution for everything DIY
View Video

Henkel

Henkel - Setting the course for tomorrow with a clear sustainability strategy
View Video

Yokoy Group

YOKOY - more than just digitised invoices.
View Video

IAR Systems

IAR - Transition from an Internet of Broken Things to an Internet of Trust
View Video

Palladium Equity Partners

Palladium Equity Partners - Investing for all Stakeholders
View Video

ATOSS

ATOSS Software AG – shaping tomorrow’s working environments
View Video

IWC Schaffhausen

IWC Schaffhausen - A Responsible and Transparent Strategy from a Leading Manufacturer of Luxury Watches
View Video

Borussia Dortmund

Borussia Dortmund - A football club taking on responsibilities
View Video

Africa Finance Corporation

Africa Finance Corporation - Developing a Continent Through Carefully Managed Projects and Initiatives
View Video

Terra Firma

Terra Firma – Rethinking private equity in a changing investment landscape
View Video

RMS

RMS – Actionable risk insights in the era of climate change
View Video

BetterUp

BetterUp – The Democratization of Personalized Coaching
View Video

Lekoil

LekOil – Improving Lives and Adapting to the Changing Priorities of the Energy Market
View Video

Ecor Global

Noble Environmental Technologies – Invents Fiber Alloys® Creating Next Generation Design Materials
View Video

APPLY AND BE PART OF DAVOS 2024

APPLY HERE
Presented By